MIAMI--(BUSINESS WIRE)--SafeStitch Medical®, Inc. (OTCBB:SFES), SafeStitch Medical today reported positive findings in a seven patient preliminary pilot clinical trial using its proprietary transluminal devices to restrict gastric acid reflux in three patients and to cause meaningful weight reduction in two obese patients after two years.
